Intratumorally CpG immunotherapy with carbon nanotubes inhibits local tumor growth and liver metastasis by suppressing the epithelial–mesenchymal transition of colon cancer cells
Authors:
Open Access
- 25 September 2020
- journal article
- research article
- Published by Wolters Kluwer Health in Anti-Cancer Drugs
- Vol. 32 (3) , 278-285
Abstract
Colon cancer liver metastasis accounts for the major cause of death of colon cancer patients. Previous study reported a carbon nanotubes (CNT)-conjugated CpG complex (CNT-CpG), which displayed a significant antitumor effect in gliomas. However, whether CNT-CpG could limit colon tumor growth and suppress the colon cancer liver metastasis has not been evaluated. In this study, we report CNT enhances CpG uptake in mouse colon cancer cells. Results demonstrated only CpG with CNT conjugation showed significant activation of NF-κB signal. Moreover, intratumorally delivery of CNT-CpG successfully suppressed local xenograft tumor growth and liver metastasis. CNT-CpG treatments cured 75% of mice and inhibited local tumor growth, significantly prolonged survival outcomes and limited liver metastatic tumor nodules from colon cancer cells. Using human colon cancer cell line, HCT116, we observed significantly inhibitory effects of CNT-CpG on cell growth, invasion and migration. Importantly, CNT-CpG treatment blocked the epithelial to mesenchymal transition (EMT). We compared the mRNA levels of EMT markers of colon cancer cells without or with CNT-CpG treatment from in-vitro and in-vivo models. Consistent results demonstrated expression of epithelial marker, E-cadherin was upregulated by CNT-CpG. In contrast, three mesenchymal markers, snail, fibronectin and vimentin were significantly suppressed by CNT-CpG treatment compared with control or free CpG. In summary, our data suggest CNT-CpG is an effective therapeutic approach against local colon tumor and their liver metastasis. This study presents the CNT-CpG complex as a promising therapeutic target for developing novel therapies against both local colon tumors and liver metastatic tumors.Keywords
This publication has 21 references indexed in Scilit:
- Notch Suppresses Angiogenesis and Progression of Hepatic MetastasesCancer Research, 2015
- Doxycycline Inducible Kruppel-Like Factor 4 Lentiviral Vector Mediates Mesenchymal to Epithelial Transition in Ovarian Cancer CellsPLOS ONE, 2014
- Intracerebral CpG Immunotherapy with Carbon Nanotubes Abrogates Growth of Subcutaneous Melanomas in MiceClinical Cancer Research, 2012
- Carbon Nanotubes Enhance CpG Uptake and Potentiate Antiglioma ImmunityClinical Cancer Research, 2011
- Inflammation and Colon CancerGastroenterology, 2010
- Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II studyNeuro-Oncology, 2010
- Preparation of carbon nanotube bioconjugates for biomedical applicationsNature Protocols, 2009
- Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF‐3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanomaCancer, 2009
- In vitro and in vivo effects of CpG-Oligodeoxynucleotides (CpG-ODN) on murine transitional cell carcinoma and on the native murine urinary bladder wall.2009
- Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma1Neuro-Oncology, 2006